NCT06953193

Brief Summary

This randomized clinical trial compares the hemodynamic effects of general anesthesia versus combined general anesthesia (thoracic epidural) in patients undergoing pancreatoduodenectomy. The primary aim is to assess the incidence of intraoperative hypotension and related adverse events. Secondary outcomes includes vasopressor requirements, transfusion needs, postoperative complications, intensive care unit admission, hospital length of stay, and mortality.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
206

participants targeted

Target at P75+ for not_applicable

Timeline
49mo left

Started Apr 2025

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress21%
Apr 2025Apr 2030

First Submitted

Initial submission to the registry

April 7, 2025

Completed
Same day until next milestone

Study Start

First participant enrolled

April 7, 2025

Completed
24 days until next milestone

First Posted

Study publicly available on registry

May 1, 2025

Completed
4.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 7, 2030

Expected
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2030

Last Updated

April 1, 2026

Status Verified

April 1, 2025

Enrollment Period

4.8 years

First QC Date

April 7, 2025

Last Update Submit

March 27, 2026

Conditions

Keywords

Pancreatic SurgeryGeneral AnesthesiaHemodynamic ChangesVasopressorsPostoperative ComplicationsCombined Anesthesia

Outcome Measures

Primary Outcomes (1)

  • Incidence of Intraoperative Hypotension

    Defined as the occurrence of any mean arterial pressure (MAP) \<65 mmHg during the intraoperative period, measured continuously with an invasive arterial line or intermittently with a non-invasive blood pressure monitor, as available.

    From induction of anesthesia to end of surgery (intraoperative period).

Secondary Outcomes (7)

  • Type of Vasopressor Administered

    From induction of anesthesia to end of surgery.

  • Estimated Blood Loss

    From start to end of surgery.

  • Number of Blood Transfusions

    From start to end of surgery.

  • ICU Admission Rate

    Within 24 hours after surgery.

  • Length of Hospital Stay

    Up to 60 days after surgery

  • +2 more secondary outcomes

Study Arms (2)

General Anesthesia

ACTIVE COMPARATOR

Patients will receive general anesthesia for pancreatoduodenectomy. Standardized anesthetic technique will be used with induction and maintenance based on institutional protocols, including intravenous induction agents, inhalational anesthetics, and intraoperative monitoring. No epidural catheter will be placed.

Procedure: General Anesthesia

Combined General Anesthesia (Thoracic Epidural)

EXPERIMENTAL

Patients will receive combined general anesthesia (thoracic epidural) for pancreatoduodenectomy. Standardized general anesthesia will be administered as in the general anesthesia group, with the addition of a thoracic epidural catheter placed before induction and maintained intraoperatively with local anesthetics according to institutional protocol.

Procedure: Combined General Anesthesia (Thoracic Epidural)

Interventions

Patients will undergo balanced general anesthesia for pancreatoduodenectomy. Induction will include: fentanyl 4 mcg/kg, lidocaine 1 mg/kg, propofol 1.5 mg/kg, and rocuronium 0.6 mg/kg. Anesthesia maintenance will be achieved with sevoflurane (variable concentration as per anesthesiologist discretion) and continuous fentanyl infusion according to the attending anesthesiologist's judgment. No epidural catheter will be placed.

General Anesthesia

Patients will undergo combined general anesthesia (thoracic epidural) for pancreatoduodenectomy. Induction will include: fentanyl 4 mcg/kg, lidocaine 1 mg/kg, propofol 1.5 mg/kg, and rocuronium 0.6 mg/kg. A thoracic epidural catheter will be placed at the best palpable intervertebral space between T6-T9 by the attending anesthesiologist. Anesthesia maintenance will include sevoflurane (variable concentration), fentanyl infusion at the anesthesiologist's discretion, and continuous infusion of 0.25% bupivacaine via the epidural catheter throughout the surgery.

Combined General Anesthesia (Thoracic Epidural)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Signed written informed consent.
  • Patients scheduled for elective pancreatoduodenectomy at National Institute of Medical Sciences and Nutrition Salvador Zubirán.
  • No contraindications for neuroaxial anesthesia (epidural catheter placement), including:
  • Generalized or localized infection at the puncture site.
  • Thrombocytopenia.
  • Coagulation disorders.
  • Intracranial hypertension.
  • Patient refusal.

You may not qualify if:

  • Age under 18 years.
  • Pregnancy.
  • Inability to randomize the case due to specific circumstances (such as contraindications to epidural use), resulting in non-eligibility based on participation criteria.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

Mexico City, Mexico City, 14080, Mexico

RECRUITING

MeSH Terms

Conditions

Pancreatic NeoplasmsHypotensionPostoperative Complications

Interventions

Anesthesia, GeneralTea

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteNeoplasmsEndocrine Gland NeoplasmsDigestive System DiseasesPancreatic DiseasesEndocrine System DiseasesVascular DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

AnesthesiaAnesthesia and AnalgesiaPlant PreparationsBiological ProductsComplex MixturesBeveragesDiet, Food, and NutritionPhysiological PhenomenaFood and Beverages

Central Study Contacts

Rafael P. Leal Villalpando, MD

CONTACT

Diana E. Díaz Arizmendi, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
Both the investigator and the outcomes assessor will be blinded to the group assignment. Care providers will not be blinded.
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Chief of the Department of Anesthesiology

Study Record Dates

First Submitted

April 7, 2025

First Posted

May 1, 2025

Study Start

April 7, 2025

Primary Completion (Estimated)

January 7, 2030

Study Completion (Estimated)

April 30, 2030

Last Updated

April 1, 2026

Record last verified: 2025-04

Data Sharing

IPD Sharing
Will not share

Locations